Imatinib Accord (Imatinib)

Imatinib binds to the ATP‑binding site of the BCR‑ABL fusion protein and other kinases such as c‑KIT and PDGFR. This blocks phosphorylation of downstream signaling molecules, halting proliferative pathways and inducing cell‑cycle arrest and apoptosis in cancer cells that rely on these kinases for survival.

The dosage of Imatinib Accord is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, weight, renal and hepatic function, and other clinical factors. Only a qualified health‑care professional can determine the appropriate dose and schedule.

Safety data for imatinib in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives and risk mitigation with their health‑care provider.

To place an order, submit an enquiry on the Imatinib Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer TKIs such as dasatinib and nilotinib may offer faster molecular responses in some patients, but imatinib’s long‑term safety profile and extensive clinical experience make it a widely used reference therapy.

Imatinib Accord should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency.

Imatinib Accord is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow the specific instructions provided by their prescriber to ensure consistent absorption.

Serious adverse events include hepatotoxicity, severe neutropenia or thrombocytopenia, and cardiac complications such as left‑ventricular dysfunction or heart failure. Patients should be monitored regularly for liver enzymes, blood counts and cardiac function, and any concerning symptoms should be reported promptly.

Imatinib Accord is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those receiving strong CYP3A4 inducers or inhibitors that could alter drug exposure.